Yesterday's chemistry piece covered what a purity number on a certificate of analysis actually measures. Here is the part that certificate does not touch at all.
Purity is a question about a molecule. Sterility is a question about a room.
The Rulebook Is About The Room
The standard that governs compounded sterile preparations in the US is USP General Chapter 797, which became official on November 1, 2023. Read its stated purpose and you notice something: almost none of it is about the drug. It exists to prevent microbial contamination, excessive bacterial endotoxins, strength that drifts outside limits, unintended chemical and physical contaminants, and ingredients of poor quality.
Those are process failures, not molecule failures. So the requirements are process requirements: aseptic work performed inside a certified ISO Class 5 critical area, HEPA-filtered air moving in one direction over the exposed product, environmental and personnel monitoring, gowning that never touches the floor, and simulated production runs to prove the procedure holds up under the worst case.
What The FDA Says Goes Wrong
The FDA keeps a running catalog of what it has actually found in facilities. Its guidance on insanitary conditions at compounding facilities lists real observations: vermin and dogs near production, visible mold in the clean area, rust and glass shavings and hair, unsealed ceiling tiles, sinks and floor drains in the wrong room.
Two lines in that document matter most here.
First, using an ingredient labeled "not for pharmaceutical use" or the equivalent is itself an insanitary condition. That is the exact label on most grey-market vials, and the FDA treats it as a defect in the process, not a disclaimer that fixes anything.
Second, the agency notes that a passing sterility test is not proof a batch is sterile, because contamination is not spread evenly through a lot. Sterility is bought by controlling the process, not by testing a sample afterward. A one-page PDF emailed with a vial is testing after the fact, at best.
Why This Is An Argument For The Legal Path
In 2012, injectable products from a compounding facility caused a fungal meningitis outbreak with more than 750 infections and 60 deaths. That is not an argument against compounding. It is the reason this rulebook exists, and the reason a licensed facility can be inspected, ordered to recall, and shut down. Under the law, no compounding exemption protects a drug produced under insanitary conditions.
None of that machinery reaches an anonymous shipment. There is no lot number to recall, no inspector, no state board, no address. When the process fails, nobody finds out.
That is Peppies' position, stated plainly: the danger in this story sits in the supply chain, not in the molecule. A legal, tested, prescription pathway is the only version of this where somebody is accountable for the room. Follow where that pathway stands on our regulatory tracker, and see the rest of our safety coverage.
No peptide discussed here is FDA-approved. These products have not been evaluated by the FDA, and Peppies makes no claim that any peptide is safe or effective. Peppies does not sell peptides. We are a disclosed advocate for a legal, tested pathway.
By Peppies.